Venue: Botnar Research Centre (G54 & G38 meeting rooms)
Theme: Engaging with Industry
Sir Professor Marc Feldmann is an immunologist, and a professor at the University of Oxford. After graduating with an MBBS degree from the University of Melbourne in 1967, he earned a Ph.D. in Immunology at the Walter and Eliza Hall Institute of Medical Research in 1972. He moved to London in the 1970s, working at Imperial Cancer Research Fund’s Tumour Immunology Unit, then in 1985 moved to the Charing Cross Sunley Research Centre and the Kennedy Institute of Rheumatology. The Kennedy Institute joined with the Faculty of Medicine at Imperial College in 2000 and in August 2011 the Kennedy Institute of Rheumatology transferred to the University of Oxford.
Chas Bountra is Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford. He is also a Visiting Professor in Neuroscience and Mental Health at Imperial College, London. Chas is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes. Chas believes the SGC has become a leader in human protein structural biology and epigenetics chemical biology, and is arguably one of the most successful open innovation, public – private partnerships in the world. Furthermore, with the many recent local developments (Target Discovery Institute, Kennedy Institute, Dementia Institute), he believes Oxford is emerging as one of the major academic drug discovery centres in Europe.He has given over 300 invited lectures. In 2012 he was voted one of the “top innovators in the industry”.
Making the most of your expertise
Miss Kerry Antcliffe
With a background in Law, Kerry joined Isis in December 2005 as OUC’s Project Administrator and was later promoted to be the group’s Project Co-ordinator. She is now an experienced Project Manager, working alongside a Senior Project Manager. Kerry manages a portfolio of her own projects drawn from across the University but with a particular emphasis on the Medical Sciences Division.
Making the most of your intellectual property
Dr Paul Ashley
Paul joined Isis as a Technology Transfer Team Leader in July 2011. Paul runs a team of life science technology transfer managers with a broad range of commercial and scientific experience, including drug development, medical technologies, immunology, genetics, biomarkers, vaccines, biochemistry and cell biology. Notable commercialisation projects include a strategic role in a vaccine joint venture, the creation of number of spin out companies in the fields of gene therapy, vaccine production and medical devices and completion of a range of life science technology licensing agreements. Paul is the relationship manager for a number of important charitable funders and partners.
Dr Alex Liakos MBBS MRCP BA
Alex is the Medical Lead for Inflammation for Pfizer in the UK. He joined the pharmaceutical industry 3 years ago from the NHS where he was a Specialist Registrar in Rheumatology in the South East of England. He is a member of the Royal College of Physicians, and has a first class degree in English Literature.
Samantha Howland MRPharmS
Sam is the Medical Lead for Rare Diseases, Respiratory Medicine and Women’s Health for Pfizer UK having moved from a previous role in the Inflammation medical team. She is a pharmacist by training and moved into the industry 10 years ago. Working in different companies and different non-commercial roles has given Sam a perspective on the role of the pharmaceutical industry and career opportunities for driven individuals with experience of life sciences or medicine.